Rx-To-OTC Switches "Not In Financial Interests" Of Manufacturers - Juhl
This article was originally published in The Tan Sheet
Executive Summary
Three years of market exclusivity following an Rx-to-OTC switch might not be enough of an incentive to encourage manufacturers to apply for switches, former FDA Nonprescription Drugs Advisory Committee chair Randy Juhl, PhD, University of Pittsburgh, suggested at the American Pharmaceutical Association annual meeting March 11.
You may also be interested in...
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
An initiative promoting Prilosec OTC over prescription competitors to help Medicare Part D users avoid "the coverage gap" in their prescription costs may prompt a closer look at ways Medicare can pay for OTCs
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
An initiative promoting Prilosec OTC over prescription competitors to help Medicare Part D users avoid "the coverage gap" in their prescription costs may prompt a closer look at ways Medicare can pay for OTCs
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
An initiative promoting Prilosec OTC over prescription competitors to help Medicare Part D users avoid "the coverage gap" in their prescription costs may prompt a closer look at ways Medicare can pay for OTCs